Skip to main content
Supriya Lifescience Limited logo

Supriya Lifescience Limited — Investor Relations & Filings

Ticker · SUPRIYA ISIN · INE07RO01027 LEI · 894500RBVJX1EOJP0Y02 BSE.NS Manufacturing
Open in API
Filings indexed 475 across all filing types
Latest filing 2022-11-25 Investor Presentation
Country IN India
Listing BSE.NS SUPRIYA

About Supriya Lifescience Limited

https://www.supriyalifescience.com

Supriya Lifescience Limited is a research-driven manufacturer of Active Pharmaceutical Ingredients (APIs) with a focus on diverse therapeutic segments. The company specializes in the production of antihistamines, anti-allergics, vitamins, anesthetics, and anti-asthmatics. Its core product portfolio includes Chlorpheniramine Maleate, Ketamine Hydrochloride, and Salbutamol Sulphate, maintaining a significant global market share in these niche categories. Operating with a strong emphasis on backward integration, the firm ensures supply chain reliability and cost efficiency. The manufacturing infrastructure is compliant with international regulatory standards, including approvals from the USFDA, EDQM, and PMDA. Supriya Lifescience serves a broad international clientele across more than 100 countries, catering to both regulated and semi-regulated markets through its advanced R&D capabilities and commitment to quality excellence.

Recent filings

Filing Released Lang Actions
Schedule of Analysts/Institutional Investor Meet/Con. Call
Investor Presentation Classification · 95% confidence The document is a letter addressed to stock exchanges informing about a schedule of analyst/institutional investor meetings as per SEBI regulations. It mentions that an Investor Presentation was referred to during the meeting and that the presentation has already been uploaded on the company's website and stock exchanges. The document explicitly states it is an announcement about the schedule and reference to the Investor Presentation, not the presentation itself. The document length is short (2032 characters), and it serves as a notification rather than containing detailed financial data or the presentation content. Therefore, it fits the category of an Investor Presentation announcement or notification. According to the filing definitions, this is best classified as an Investor Presentation (IP) since it relates to investor meetings and presentations, and the document is about the presentation referenced in the meeting.
2022-11-25 English
Schedule of Analysts/Institutional Investor Meet/Con. Call
Regulatory Filings
2022-11-23 English
Schedule of Analysts/Institutional Investor Meet/Con. Call
Investor Presentation Classification · 95% confidence The document is a letter addressed to stock exchanges informing about a scheduled analyst/institutional investor meeting. It mentions that an Investor Presentation has been uploaded on the company's website and stock exchanges. The document is short (2223 characters) and serves as a notification rather than containing the presentation itself. It is an announcement related to investor meetings and presentations, not the presentation document itself. Therefore, it fits the category of Investor Presentation (IP) as it informs about the presentation and meeting with investors.
2022-11-22 English
Transcript of Analysts/Institutional Investor Meet/Con. Call
Call Transcript Classification · 100% confidence The document is a detailed transcript of an earnings conference call held on November 11, 2022, discussing the financial and operational performance of Supriya Lifescience Limited for the quarter and half year ended September 30, 2022. It includes management commentary, financial figures, business updates, and Q&A format typical of earnings call transcripts. The document references specific fiscal periods (Q2 and H1 FY23) and contains substantive financial data and management discussion. It is not merely an announcement or a brief summary but a full transcript of the call. Therefore, the appropriate classification is Call Transcript (CT).
2022-11-17 English
Related Party Transaction
Regulatory Filings Classification · 95% confidence The document is a disclosure of Related Party Transactions pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It provides detailed financial data on related party transactions for the half year ended September 30, 2022, including remuneration, loans, rent, dividends, and other transactions involving key management personnel and promoters. The document is not an annual or interim report but a regulatory disclosure specific to related party transactions. It is not a certification or announcement of a report but contains substantive financial data. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2022-11-17 English
Newspaper Advertisements
Regulatory Filings
2022-11-14 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.